1. Home
  2. ACRS vs SAFE Comparison

ACRS vs SAFE Comparison

Compare ACRS & SAFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$5.17

Market Cap

868.5M

Sector

Health Care

ML Signal

HOLD

Logo Safehold Inc. New

SAFE

Safehold Inc. New

HOLD

Current Price

$12.35

Market Cap

1.0B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACRS
SAFE
Founded
2012
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
868.5M
1.0B
IPO Year
2015
1999

Fundamental Metrics

Financial Performance
Metric
ACRS
SAFE
Price
$5.17
$12.35
Analyst Decision
Strong Buy
Hold
Analyst Count
5
10
Target Price
$10.20
★ $19.00
AVG Volume (30 Days)
★ 2.4M
371.1K
Earning Date
05-07-2026
04-30-2026
Dividend Yield
N/A
★ 4.48%
EPS Growth
★ 69.01
7.43
EPS
N/A
★ 0.82
Revenue
$1,683,000.00
★ $385,552,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.24
$4.31
P/E Ratio
★ N/A
$15.10
Revenue Growth
N/A
★ 5.43
52 Week Low
$1.74
$12.38
52 Week High
$6.60
$17.45

Technical Indicators

Market Signals
Indicator
ACRS
SAFE
Relative Strength Index (RSI) 39.06 18.71
Support Level $4.99 N/A
Resistance Level $5.87 $16.43
Average True Range (ATR) 0.36 0.44
MACD -0.05 -0.15
Stochastic Oscillator 15.38 3.59

Price Performance

Historical Comparison
ACRS
SAFE

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

About SAFE Safehold Inc. New

Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.

Share on Social Networks: